• Amylin Pharmaceuticals Inc., of San Diego, said initial purchasers in its recent private placement of $150 million of 2.25 percent convertible senior notes due in 2008 elected to exercise their option to purchase another $25 million in principal amount of the notes. The closing for the additional $25 million purchase is expected Tuesday. Amylin intends to use the proceeds for research and development, the planned commercialization of its diabetes product, Symlin, pending regulatory approvals, and general corporate purposes, it said. (See BioWorld Today, June 18, 2003.)

• Antisoma plc, of London, said it would complete its pivotal Phase III SMART study of R1549 (formerly called pemtumomab) in ovarian cancer between December and February, earlier than previous guidance that ranged between February and next August. The company added that the trial's independent data safety monitoring committee found no unexpected safety concerns or other reasons why the trial should not continue as planned. Antisoma is co-developing R1549 and other cancer products with F. Hoffmann-La Roche Ltd., of Basel, Switzerland.

• Bio-Rad Laboratories Inc., of Hercules, Calif., intends to offer up to $200 million aggregate principal amount of senior subordinated notes in a private offering. The company intends to use a portion of the proceeds to fund the purchase of its outstanding 11 5/8 percent senior subordinated notes due 2007. Separately, it then commenced a cash tender offer for all of the approximately $88.7 million aggregate principal amount of the 11 5/8 percent notes. The company is soliciting holders to consent to proposed amendments to the indenture governing the notes, which would eliminate substantially all of the restrictive covenants and certain related terms, it said. Bio-Rad is a manufacturer and distributor of life science research products and clinical diagnostics.

• Forbes Medi-Tech Inc., of Vancouver, British Columbia, signed a licensing and sales agreement with Iljin Pharmaceutical Co. Ltd. to supply Reducol for use in dietary supplements and functional food products in South Korea. Forbes will supply Reducol from its manufacturing joint venture, Phyto-Source LP, of Pasadena, Texas, with shipments expected to begin in the fourth quarter and launch scheduled for the first quarter of next year. Forbes said it expects Korean regulatory approval later this year.

• GenTel BioSurfaces Inc., of Madison, Wis., named Alex Vodenlich president. Most recently, he was the vice president of contract services at PanVera LLC, also of Madison, which was bought earlier this year by Invitrogen Corp., of Carlsbad, Calif. Founded in 2000 as a spin-off from the University of Wisconsin at Madison, privately held GenTel's technology is centered on surface chemistries used for detection techniques, microfluidics and applications development.

• IDEC Pharmaceuticals Corp., of San Diego, reported second-quarter results. It posted net income of $28.8 million, or 17 cents per share on a diluted basis. However, excluding a one-time signing payment paid to Genentech Inc., of South San Francisco, related to an anti-CD20 antibody development collaboration, the company would have posted net income of $41.2 million, or 24 cents per share on a diluted basis. Total revenues were $123.6 million, including $118.4 million recorded for IDEC's joint business arrangement with Genentech for Rituxan. Revenues also included $5 million in net U.S. sales of Zevalin. The company ended the quarter with $1.5 billion in cash, cash equivalents and securities available for sale.

• NexMed Inc., of Robbinsville, N.J., reported primary efficacy data at the American Urological Association meeting showing that the ejaculatory latency time increased to more than two minutes in 53.5 percent of patients using its alprostadil/lidocaine/NexACT cream treatment as part of a premature ejaculation study. Sexual satisfaction, a secondary endpoint as assessed by the patients and their partners, reached 72.1 percent and 67.4 percent, respectively. In the control group, 12.5 percent of patients reported a mean ejaculatory latency time of more than 2 minutes. The three-month, multicenter, single-blinded pilot study enrolled 51 patients, sending eight to the alprostadil control group and 43 into the combination treatment group.

• Nonlinear Dynamics Ltd., of Newcastle upon Tyne, UK, said it did not renew its contract to supply its 2-D gel analysis software to the proteomics group at Amersham Biosciences, of Piscataway, N.J., a division of Amersham plc. The agreement dated to 1996, when Nonlinear was chosen as Amersham's supplier of 1-D and 2-D gel analysis software, distributed under the ImageMaster brand.

• PrimaBioMed Ltd., of Victoria, Australia, said four more patients were successfully treated in a Phase Ib trial of an investigational immunotherapy developed by its subsidiary, Cancer Vac. No significant side effects have been seen and the therapy is showing positive effects on tumors in some patients, PrimaBioMed said, adding that two patients who have continued therapy for 18 months have experienced no progression of their disease. The company said Phase II plans are under way.

• Therascope AG, of Heidelberg, Germany, completed a 124.1 million second round of institutional preferred stock financing. The company also said it is changing its name from Therascope to Alantos Pharmaceuticals, expected to be finalized in August. Proceeds will be used for the advancement of drug discovery projects using its TACE (Target Amplified drug Candidate Evolution) technology, which merges synthesis of new chemical entities and identification of target binders into one step. Earlybird Venture Capital, of Hamburg, Germany, acted as local co-lead for the round. Matthias Jaffe, a principal at Earlybird, joined Therascope as vice president of finance. The round brings the total amount raised by Therascope to more than 127 million. Other new investors include ABN AMRO, of Amsterdam, the Netherlands; Schroder Ventures Life Sciences, of London; and Ventech, of Paris. Returning investors include Auriga Ventures, of Paris, and Heidelberg Innovation, of Heidelberg.

• ZymoGenetics Inc., of Seattle, reported findings at the International Society on Thrombosis and Haemostasis Congress in Birmingham, UK, showing that CTRP1, a protein discovered through its bioinformatics-driven discovery efforts, has potent anti-thrombotic activities without causing adverse bleeding events. ZymoGenetics added that CTRP1, also called zsig37, might provide a new mechanism of action for the prevention and treatment of thrombotic complications associated with various types of vascular injuries, while minimizing the potential for bleeding complications.